ArticleFrontiers in oncology2019

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.

Man Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.